Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 337

1.

Schizophrenia, obesity, and antipsychotic medications: what can we do?

Citrome L, Vreeland B.

Postgrad Med. 2008 Jul;120(2):18-33. doi: 10.3810/pgm.2008.07.1786. Review.

PMID:
18654065
2.

[Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].

Ruetsch O, Viala A, Bardou H, Martin P, Vacheron MN.

Encephale. 2005 Jul-Aug;31(4 Pt 1):507-16. Review. French.

PMID:
16389718
3.

Management of weight gain associated with antipsychotics.

Birt J.

Ann Clin Psychiatry. 2003 Mar;15(1):49-58. Review.

PMID:
12839432
4.

Antipsychotic induced weight gain in schizophrenia:mechanisms and management.

Rege S.

Aust N Z J Psychiatry. 2008 May;42(5):369-81. doi: 10.1080/00048670801961123. Review.

PMID:
18473255
5.
6.

Management of weight gain in patients with schizophrenia.

Aquila R.

J Clin Psychiatry. 2002;63 Suppl 4:33-6. Review.

7.

The clinical implications of weight gain in schizophrenia.

Kurzthaler I, Fleischhacker WW.

J Clin Psychiatry. 2001;62 Suppl 7:32-7. Review.

8.

Antipsychotic medications: metabolic and cardiovascular risk.

Newcomer JW.

J Clin Psychiatry. 2007;68 Suppl 4:8-13. Review.

9.

Weight gain from novel antipsychotic drugs: need for action.

Green AI, Patel JK, Goisman RM, Allison DB, Blackburn G.

Gen Hosp Psychiatry. 2000 Jul-Aug;22(4):224-35. Review.

PMID:
10936629
10.

The role of lifestyle interventions and weight management in schizophrenia.

Bushe C, Haddad P, Peveler R, Pendlebury J.

J Psychopharmacol. 2005 Nov;19(6 Suppl):28-35. Review.

PMID:
16280335
11.

Metabolic risk during antipsychotic treatment.

Newcomer JW.

Clin Ther. 2004 Dec;26(12):1936-46. Review.

PMID:
15823759
12.

[Weight gain during treatment with antipsychotics: clinical relevance, pathophysiology, and therapeutical strategies].

Himmerich H, Schuld A, Pollm├Ącher T.

Psychiatr Prax. 2004 Nov;31 Suppl 2:S233-7. Review. German.

PMID:
15586316
13.

Increased cardiovascular risk with second-generation antipsychotic agent switches.

Ried LD, Renner BT, McConkey JR, Bengtson MA, Lopez LM.

J Am Pharm Assoc (2003). 2006 Jul-Aug;46(4):491-8; quiz 499-501. Review.

PMID:
16913393
14.

Schizophrenia and obesity: impact of antipsychotic medications.

Wirshing DA.

J Clin Psychiatry. 2004;65 Suppl 18:13-26. Review.

15.

Management of atypical antipsychotic drug-induced weight gain: focus on metformin.

Miller LJ.

Pharmacotherapy. 2009 Jun;29(6):725-35. doi: 10.1592/phco.29.6.725. Review.

PMID:
19476423
16.

Management of schizophrenia with obesity, metabolic, and endocrinological disorders.

Monteleone P, Martiadis V, Maj M.

Psychiatr Clin North Am. 2009 Dec;32(4):775-94. doi: 10.1016/j.psc.2009.08.003. Review.

PMID:
19944883
17.

Weight gain associated with use of psychotropic medications.

Sachs GS, Guille C.

J Clin Psychiatry. 1999;60 Suppl 21:16-9. Review.

18.
19.

Obesity, serious mental illness and antipsychotic drugs.

Holt RI, Peveler RC.

Diabetes Obes Metab. 2009 Jul;11(7):665-79. doi: 10.1111/j.1463-1326.2009.01038.x. Epub 2009 May 19. Review.

PMID:
19476478
20.

[Metabolic risk during antipsychotic treatment in patients with schizophrenia].

Rzewuska M.

Psychiatr Pol. 2007 Jul-Aug;41(4):457-72. Review. Polish.

PMID:
18046977

Supplemental Content

Support Center